Skip to main content

Table 1 Comparison of demographic and post-transplant characteristics between patients maintaining a full dose and patients with at least one dose reduction in trimethoprim-sulfamethoxazole in the first 12 months post-kidney transplantation

From: Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

Parameter

Full Dose Group (N = 233)

Reduced Dose Group (N = 205)

P value

Age at transplantation (years) (mean ± SD, range)

52.5 ± 13 (19–81)

54.1 ± 12 (24–76)

0.22

Sex (N, %)

  

0.42

Male

144 (62)

119 (58)

 

Female

89 (38)

86 (42)

 

Donor Source (N, %)

  

0.002

Deceased

142 (61)

154 (75)

 

Live

91 (39)

51 (25)

 

Number of transplants

  

0.4

One

224 (97)

194 (96)

 

Two

7 (3)

9 (4)

 

Cause of end-stage kidney disease (N, %)

 Diabetes

41 (18)

44 (22)

0.30

 Hypertension

25 (11)

19 (9)

0.61

 Glomerulonephritis

94 (40)

78 (38)

0.62

 Polycystic kidney disease

23 (10)

28 (14)

0.21

 Congenital kidney disease

10 (4)

7 (3)

0.63

 Others

40 (17)

29 (14)

0.28

Ethnicity

 Caucasian

94 (40)

70 (34)

0.13

 Black

16 (7)

21 (10)

0.20

 East Asian

32 (14)

20 (10)

0.19

 South Asian

47 (20)

53 (26)

0.15

 Other

43 (19)

41 (20)

0.71

Pre-transplant dialysis modality (N, %)

  

0.015

Hemodialysis

122 (53)

131 (64)

 

Peritoneal dialysis

69 (30)

54 (27)

 

Preemptive

36 (17)

18 (9)

 

Dialysis duration (days) (mean ± SD)

1790 ± 1315

2052 ± 1427

0.06

Cytomegalovirus IgG antibody N (%)

174 (75)

167 (81)

0.18

Epstein Barr virus IgG antibody N (%)

211 (91)

189 (93)

0.70

Hepatitis B surface antigen N (%)

4 (2)

3 (1)

0.29

Hepatitis C antibody N (%)

4 (2)

2 (1)

0.41

HIV antibody N (%)

2 (1)

4 (2)

0.29

Tuberculin skin test positive N (%)

31 (13)

11 (5)

0.33

Cumulative Panel Reactive Antibody (%)(mean ± SD, range)

7.5 ± 20 (0–99)

13.5 ± 28 (0–100)

0.02

History of smoking (N, %)

94 (42)

56 (28)

0.003

Delayed graft function N (%)

38 (16)

41 (20)

0.31

Acute rejection N (%)

7 (3)

18 (9)

0.009

Post-transplant diabetes (N, %)

19 (8)

16 (8)

0.81

Graft loss N (%)

2 (1)

0 (0)

0.28

Immunosuppressive medication at discharge (N, %)

 Tacrolimus

215 (93)

189 (93)

0.99

 Cyclosporine

11 (5)

14 (7)

0.34

 Mycophenolate mofetil

104 (45)

80 (39)

0.23

 or mycophenolic acid

103 (45)

95 (44)

0.64

 Azathioprine

11 (5)

4 (2)

0.09

 Prednisone

219 (95)

196 (97)

0.37

Other medication (N, %)

 Angiotensin-converting enzyme inhibitor

12 (5)

9 (4)

0.71

 Angiotensin II receptor blocker

19 (8)

24 (12)

0.21

 Non-dihydropyridine calcium channel blocker

21 (9)

13 (6)

0.28

 Dihydropyridine calcium channel blocker

100 (43)

100 (49)

0.21

 Beta blocker

87 (37)

90 (44)

0.15

 Alpha blocker

23 (10)

19 (9)

0.83

 Loop diuretic

10 (4)

12 (6)

0.29

 Thiazide diuretic

4 (2)

4 (2)

0.56

  1. Abbreviations: IgG immunoglobulin G, SD standard deviation